At what lower end of recurrence risk do you offer adjuvant imatinib for patients with resected GIST?
What is your preferred risk stratification model?
There does not appear to be a consensus among experts as to what cutoff in recurrence risk justifies the use, cost, and risks associated with adjuvant imatinib.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
The "lower end of recurrence risk" justifying adjuvant Imatinib is indeed a personalized decision between the provider and the patient based on risk-tolerance on both sides. In the absence of "cost-effectiveness" data, this has to be a mutual decision that works for both sides. In general, <20% risk...
Join for free or sign in to see the full answer